Nessan Bermingham

Dr. Bermingham has served as a member of F-star’s Board of Directors and as its chairman since May 2019. Dr. Bermingham previously served as F-star’s chairman and on the board of directors of F-star Alpha, F-star Beta, and F-star Delta from April 2018 to May 2019. Dr. Bermingham also served as a member of the supervisory board of F-star GmbH until May 2019. Dr. Bermingham currently serves as an Operating Partner at Khosla Ventures. From Nov 2018 to Dec 2021 Dr. Bermingham served as President, Chief Executive Officer, and director of Triplet Therapeutics and is currently Exec Chair of the Board of Directors of Triplet Therapeutics. From Nov 2018 to the present Dr. Bermingham has served as Executive Chair of Korro Bio. From March 2018 to March 2020 Dr. Bermingham served as Exec Chair of Xilio Therapeutics (fka Akrevia Therapeutics). From May 2014 to December 2017, Dr. Bermingham served as co-founder, President, and Chief Executive Officer of Intellia Therapeutics, Inc. Prior to Intellia, from 2002 to 2007 and 2012 to 2014 Dr. Bermingham held various positions at Atlas Ventures including a member of the Atlas Venture Investment Team from 2002 to 2007. Dr. Bermingham was a Howard Hughes Assoc Fellow at Baylor College of Medicine, he received a Ph.D. in Molecular Biology from Imperial College London and a B.S. from Queen’s University Belfast.